MAPT and Mental deterioration: In this longitudinal study, we showed that APOE ε4 carriers in Aβ‐positive subjects were associated with a faster cognitive decline, independent of tau load, providing evidence that APOE ε4 with Aβ pathology exhibit an increased rate of dementia over time.